|
 The news is a setback for the British drugmaker, which reported
positive results with an experimental acute asthma drug on Tuesday,
although the result may have limited read-across for Lynparza in
other cancer settings.
AstraZeneca said it was disappointed, but noted this particular
trial was unusual in using a low dose and combining Lynparza with a
standard chemotherapy.
The company has high hopes for Lynparza, which is central to its
goal of building a portfolio of compounds targeting DNA damage
response (DDR) mechanisms in cancer cells.
(Reporting by Ben Hirschler; Editing by Mark Potter)
[© 2016 Thomson Reuters. All rights
reserved.] Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
